Meloxicam Market - Regional Analysis
North American Market Insights
North America industry is set to account for largest revenue share of 33% by 2035, The growth of this market can be primarily driven by an increasing number of arthritis and other chronic pain disease patients found in this region. Besides, increasing healthcare infrastructure and escalating research and development activities in meloxicam are driving the market expansion further in the North America region during the projected period. An estimated 58.5 million US adults have been told by their doctor that they have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia, based on data from the National Health Interview Survey between 2016 and 2018.
APAC Market Insights
The meloxicam market in the Asia Pacific region is estimated to account for a notable revenue share during the forecast period. This growth can be attributed to high product demand due to the growing aging population and the increasing incidence of osteoarthritis, rheumatoid arthritis, soft tissue inflammation, traumatic pain and post-operative pain. Also, there has been surging demand for rheumatoid arthritis treatment in the region. Additionally, regional growth over the forecast period is expected to be driven by favorable reimbursement policies for generic drugs. All these factors are predicted to drive the market growth of meloxicam in the APAC region during the studied period.
